STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy

被引：78

作者：

Spitzner, Melanie ^{[1
]}

Ebner, Reinhard ^{[2
]}

Wolff, Hendrik A. ^{[3
]}

Ghadimi, B. Michael ^{[1
]}

Wienands, Juergen ^{[4
]}

Grade, Marian ^{[1
]}

机构：

[1] Univ Med Gottingen, Dept Gen Visceral & Pediat Surg, Robert Koch Str 40, D-37075 Gottingen, Germany

[2] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA

[3] Univ Med Gottingen, Dept Radiotherapy & Radiooncol, D-37075 Gottingen, Germany

[4] Univ Med Gottingen, Dept Cellular & Mol Immunol, D-37073 Gottingen, Germany

来源：

CANCERS | 2014年 / 6卷 / 04期

关键词：

STAT3; cancer; radiotherapy; chemoradiotherapy; chemoradiotherapy-resistance; chemoradiotherapy-sensitization; molecular target; SQUAMOUS-CELL CARCINOMA; RADIATION-INDUCED APOPTOSIS; LUNG-CANCER CELLS; ANAPLASTIC THYROID-CARCINOMA; LOCALIZED PROSTATE-CANCER; INVASIVE BLADDER-CANCER; SIGNAL TRANSDUCER; CONSTITUTIVE ACTIVATION; TRANSCRIPTION; ENHANCES RADIOSENSITIVITY;

D O I：

10.3390/cancers6041986

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemoradiotherapy (CRT) represents a standard treatment for many human cancers, frequently combined with radical surgical resection. However, a considerable percentage of primary cancers are at least partially resistant to CRT, which represents a substantial clinical problem, because it exposes cancer patients to the potential side effects of both irradiation and chemotherapy. It is therefore exceedingly important to determine the molecular characteristics underlying CRT-resistance and to identify novel molecular targets that can be manipulated to re-sensitize resistant tumors to CRT. In this review, we highlight much of the recent evidence suggesting that the signal transducer and activator of transcription 3 (STAT3) plays a prominent role in mediating CRT-resistance, and we outline why inhibition of STAT3 holds great promise for future multimodal treatment concepts in oncology.

引用

页码：1986 / 2011

页数：26

共 158 条

[1] A road map for those who don't know JAK-STAT
Aaronson, DS
Horvath, CM
[J]. SCIENCE, 2002, 296 (5573) : 1653 - 1655
[2] Achcar RDD, 2007, ARCH PATHOL LAB MED, V131, P1350
[3] Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma
Adachi, Makoto
Cui, Caixia
Dodge, Cristina T.
Bhayani, Mihir K.
Lai, Stephen Y.
[J]. ORAL ONCOLOGY, 2012, 48 (12) : 1220 - 1226
[4] [Anonymous], 2011, ISRN ONCOL
[5] [Anonymous], 2013, MOL CELL PHARM
[6] Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis
Autanski, Dirniter B.
Nagalingam, Arumugam
Bonner, Michael Y.
Arbiser, Jack L.
Saxena, Neeraj K.
Sharma, Dipali
[J]. MOLECULAR ONCOLOGY, 2014, 8 (03): : 565 - 580
[7] Management of Early and Locally Advanced Cervical Cancer
Barbera, Lisa
Thomas, Gillian
[J]. SEMINARS IN ONCOLOGY, 2009, 36 (02) : 155 - 169
[8] STAT3 modulates the DNA damage response pathway
Barry, Sean P.
Townsend, Paul A.
Knight, Richard A.
Scarabelli, Tiziano M.
Latchman, David S.
Stephanou, Anastasis
[J]. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2010, 91 (06) : 506 - 514
[9] GENOMIC INSTABILITY IN CANCER Strategies to improve radiotherapy with targeted drugs
Begg, Adrian C.
Stewart, Fiona A.
Vens, Conchita
[J]. NATURE REVIEWS CANCER, 2011, 11 (04) : 239 - 253
[10] Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence?
Bernier, J
Cooper, JS
[J]. ONCOLOGIST, 2005, 10 (03) : 215 - 224

← 1 2 3 4 5 6 7 8 9 10 →